- Home
- ONL vs ATOS Comparison
ONL vs ATOS Comparison
Compare ONL & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONL
- ATOS
- Stock Information
- Founded
- ONL 2021
- ATOS 2009
- Country
- ONL United States
- ATOS United States
- Employees
- ONL N/A
- ATOS N/A
- Industry
- ONL Real Estate Investment Trusts
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ONL Real Estate
- ATOS Health Care
- Exchange
- ONL Nasdaq
- ATOS Nasdaq
- Market Cap
- ONL 119.7M
- ATOS 107.2M
- IPO Year
- ONL N/A
- ATOS 2012
- Fundamental
- Price
- ONL $2.36
- ATOS $0.91
- Analyst Decision
- ONL Hold
- ATOS Strong Buy
- Analyst Count
- ONL 1
- ATOS 3
- Target Price
- ONL N/A
- ATOS $6.17
- AVG Volume (30 Days)
- ONL 1.0M
- ATOS 1.5M
- Earning Date
- ONL 08-06-2025
- ATOS 08-11-2025
- Dividend Yield
- ONL 3.40%
- ATOS N/A
- EPS Growth
- ONL N/A
- ATOS N/A
- EPS
- ONL N/A
- ATOS N/A
- Revenue
- ONL $154,796,000.00
- ATOS N/A
- Revenue This Year
- ONL N/A
- ATOS N/A
- Revenue Next Year
- ONL N/A
- ATOS N/A
- P/E Ratio
- ONL N/A
- ATOS N/A
- Revenue Growth
- ONL N/A
- ATOS N/A
- 52 Week Low
- ONL $1.46
- ATOS $0.55
- 52 Week High
- ONL $4.39
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- ONL 60.10
- ATOS 58.55
- Support Level
- ONL $2.29
- ATOS $0.81
- Resistance Level
- ONL $2.41
- ATOS $0.97
- Average True Range (ATR)
- ONL 0.10
- ATOS 0.05
- MACD
- ONL 0.00
- ATOS 0.01
- Stochastic Oscillator
- ONL 90.41
- ATOS 65.50
About ONL Orion Office REIT Inc.
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.